[Form 4] Nektar Therapeutics Insider Trading Activity
Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), sold a total of 11,832 shares of common stock under a Rule 10b5-1 trading plan on September 4-5, 2025. The sales were reported in several block transactions with weighted-average prices reported at $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 and $39.89. Following these dispositions the reporting person beneficially owned 56,008 shares directly; an additional 28 shares are held indirectly by the reporting person鈥檚 spouse. The filer states the transactions were effected pursuant to a 10b5-1 plan and provides price ranges for each grouped trade.
Robin W. Howard, President e CEO nonch茅 membro del consiglio di amministrazione di Nektar Therapeutics (NKTR), ha venduto complessivamente 11.832 azioni ordinarie nell'ambito di un piano di negoziazione Rule 10b5-1 nei giorni 4-5 settembre 2025. Le vendite sono state registrate in pi霉 blocchi, con prezzi medi ponderati pari a $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 e $39,89. Dopo tali operazioni la persona che ha segnalato la vendita possedeva direttamente 56.008 azioni; ulteriori 28 azioni sono detenute indirettamente dal coniuge del dichiarante. Il depositante dichiara che le transazioni sono state eseguite in conformit脿 a un piano 10b5-1 e fornisce gli intervalli di prezzo per ciascun gruppo di operazioni.
Robin W. Howard, presidente y director ejecutivo y miembro del consejo de Nektar Therapeutics (NKTR), vendi贸 un total de 11.832 acciones ordinarias bajo un plan de negociaci贸n Rule 10b5-1 los d铆as 4 y 5 de septiembre de 2025. Las ventas se informaron en varias transacciones por bloques, con precios promedio ponderados de $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 y $39.89. Tras estas disposiciones, la persona que reporta pose铆a beneficiariamente 56.008 acciones de forma directa; otras 28 acciones est谩n en manos de forma indirecta del c贸nyuge del declarante. El remitente indica que las operaciones se realizaron en virtud de un plan 10b5-1 y aporta los rangos de precio para cada grupo de operaciones.
搿滊箞 W. 頃橃泴霌�(Robin W. Howard) Nektar Therapeutics(NKTR) 靷灔 瓴� CEO, 鞚挫偓歆侅潃 2025雲� 9鞗� 4~5鞚� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 氤错喌欤� 齑� 11,832欤茧ゼ 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰電� 鞐煬 敫旊 瓯半灅搿� 鞁犼碃霅橃棃鞙茧┌, 臧�欷戫弶攴犼皜瓴╈潃 臧侁皝 $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 氚� $39.89搿� 氤搓碃霅橃棃鞀惦媹雼�. 鞚措摛 觳橂秳 鞚错泟 鞁犼碃鞚胳潃 歆侅爲鞝侅溂搿� 56,008欤茧ゼ 鞁れ 氤挫湢頃橁碃 鞛堨溂氅�, 於旉皜搿� 28欤茧姅 鞁犼碃鞚胳潣 氚办毎鞛愱皜 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞁犼碃鞛愲姅 瓯半灅臧� 10b5-1 瓿勴殟鞐� 霐半澕 鞚错枆霅橃棃鞚岇潉 氚濏瀳瓿� 臧� 攴鸽９ 瓯半灅氤� 臧�瓴� 氩旍渼毳� 鞝滉车頃╇媹雼�.
Robin W. Howard, pr茅sident-directeur g茅n茅ral et administrateur de Nektar Therapeutics (NKTR), a vendu au total 11 832 actions ordinaires dans le cadre d'un plan de n茅gociation Rule 10b5-1 les 4 et 5 septembre 2025. Les ventes ont 茅t茅 d茅clar茅es en plusieurs transactions par blocs, avec des prix moyens pond茅r茅s de 32,37 $, 33,54 $, 34,40 $, 35,80 $, 37,87 $, 38,82 $ et 39,89 $. 脌 la suite de ces cessions, la personne d茅clarante d茅tenait directement 56 008 actions ; 28 actions suppl茅mentaires sont d茅tenues indirectement par le conjoint de la personne d茅clarante. Le d茅posant indique que les transactions ont 茅t茅 effectu茅es conform茅ment 脿 un plan 10b5-1 et fournit les fourchettes de prix pour chaque groupe d'op茅rations.
Robin W. Howard, Pr盲sident & CEO sowie Director von Nektar Therapeutics (NKTR), verkaufte insgesamt 11.832 Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans am 4.鈥�5. September 2025. Die Verk盲ufe wurden in mehreren Blocktransaktionen gemeldet, mit gewichteten Durchschnittspreisen von $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 und $39,89. Nach diesen Ver盲u脽erungen besa脽 die meldende Person direkt 56.008 Aktien; weitere 28 Aktien werden indirekt von der Ehepartnerin/dem Ehepartner der meldenden Person gehalten. Der Einreicher gibt an, dass die Transaktionen gem盲脽 einem 10b5-1-Plan ausgef眉hrt wurden und nennt die Preisbereiche f眉r jede gruppierte Transaktion.
- None.
- None.
Insights
TL;DR: Insider sales of 11,832 NKTR shares occurred under a 10b5-1 plan, reducing direct holdings to 56,008 shares; transactions span $32.01鈥�$40.32.
The filing documents systematic disposals by the CEO and director executed under an established Rule 10b5-1 plan on September 4鈥�5, 2025. The report aggregates multiple trades into seven grouped line items with weighted-average prices between $32.37 and $39.89 and disclosed underlying price ranges from $32.01 to $40.32. The filing is procedural and compliant: the 10b5-1 designation and price-range disclosures signal preplanned sales rather than ad-hoc disposals. No derivative transactions or other compensatory actions are reported.
TL;DR: Report shows prearranged insider selling via 10b5-1 plan; disclosure appears complete and signed by attorney-in-fact.
The Form 4 indicates the reporting person is both an officer (President & CEO) and a director, and that the trades were made pursuant to a 10b5-1 trading plan, which provides an affirmative defense under Rule 10b5-1. The form lists the aggregated share disposals, remaining direct beneficial ownership, and an indirect 28-share holding by spouse. The form is signed by Mark A. Wilson as attorney-in-fact and includes explanatory price ranges for each grouped sale, meeting standard disclosure expectations for such filings.
Robin W. Howard, President e CEO nonch茅 membro del consiglio di amministrazione di Nektar Therapeutics (NKTR), ha venduto complessivamente 11.832 azioni ordinarie nell'ambito di un piano di negoziazione Rule 10b5-1 nei giorni 4-5 settembre 2025. Le vendite sono state registrate in pi霉 blocchi, con prezzi medi ponderati pari a $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 e $39,89. Dopo tali operazioni la persona che ha segnalato la vendita possedeva direttamente 56.008 azioni; ulteriori 28 azioni sono detenute indirettamente dal coniuge del dichiarante. Il depositante dichiara che le transazioni sono state eseguite in conformit脿 a un piano 10b5-1 e fornisce gli intervalli di prezzo per ciascun gruppo di operazioni.
Robin W. Howard, presidente y director ejecutivo y miembro del consejo de Nektar Therapeutics (NKTR), vendi贸 un total de 11.832 acciones ordinarias bajo un plan de negociaci贸n Rule 10b5-1 los d铆as 4 y 5 de septiembre de 2025. Las ventas se informaron en varias transacciones por bloques, con precios promedio ponderados de $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 y $39.89. Tras estas disposiciones, la persona que reporta pose铆a beneficiariamente 56.008 acciones de forma directa; otras 28 acciones est谩n en manos de forma indirecta del c贸nyuge del declarante. El remitente indica que las operaciones se realizaron en virtud de un plan 10b5-1 y aporta los rangos de precio para cada grupo de operaciones.
搿滊箞 W. 頃橃泴霌�(Robin W. Howard) Nektar Therapeutics(NKTR) 靷灔 瓴� CEO, 鞚挫偓歆侅潃 2025雲� 9鞗� 4~5鞚� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 氤错喌欤� 齑� 11,832欤茧ゼ 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰電� 鞐煬 敫旊 瓯半灅搿� 鞁犼碃霅橃棃鞙茧┌, 臧�欷戫弶攴犼皜瓴╈潃 臧侁皝 $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 氚� $39.89搿� 氤搓碃霅橃棃鞀惦媹雼�. 鞚措摛 觳橂秳 鞚错泟 鞁犼碃鞚胳潃 歆侅爲鞝侅溂搿� 56,008欤茧ゼ 鞁れ 氤挫湢頃橁碃 鞛堨溂氅�, 於旉皜搿� 28欤茧姅 鞁犼碃鞚胳潣 氚办毎鞛愱皜 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞁犼碃鞛愲姅 瓯半灅臧� 10b5-1 瓿勴殟鞐� 霐半澕 鞚错枆霅橃棃鞚岇潉 氚濏瀳瓿� 臧� 攴鸽９ 瓯半灅氤� 臧�瓴� 氩旍渼毳� 鞝滉车頃╇媹雼�.
Robin W. Howard, pr茅sident-directeur g茅n茅ral et administrateur de Nektar Therapeutics (NKTR), a vendu au total 11 832 actions ordinaires dans le cadre d'un plan de n茅gociation Rule 10b5-1 les 4 et 5 septembre 2025. Les ventes ont 茅t茅 d茅clar茅es en plusieurs transactions par blocs, avec des prix moyens pond茅r茅s de 32,37 $, 33,54 $, 34,40 $, 35,80 $, 37,87 $, 38,82 $ et 39,89 $. 脌 la suite de ces cessions, la personne d茅clarante d茅tenait directement 56 008 actions ; 28 actions suppl茅mentaires sont d茅tenues indirectement par le conjoint de la personne d茅clarante. Le d茅posant indique que les transactions ont 茅t茅 effectu茅es conform茅ment 脿 un plan 10b5-1 et fournit les fourchettes de prix pour chaque groupe d'op茅rations.
Robin W. Howard, Pr盲sident & CEO sowie Director von Nektar Therapeutics (NKTR), verkaufte insgesamt 11.832 Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans am 4.鈥�5. September 2025. Die Verk盲ufe wurden in mehreren Blocktransaktionen gemeldet, mit gewichteten Durchschnittspreisen von $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 und $39,89. Nach diesen Ver盲u脽erungen besa脽 die meldende Person direkt 56.008 Aktien; weitere 28 Aktien werden indirekt von der Ehepartnerin/dem Ehepartner der meldenden Person gehalten. Der Einreicher gibt an, dass die Transaktionen gem盲脽 einem 10b5-1-Plan ausgef眉hrt wurden und nennt die Preisbereiche f眉r jede gruppierte Transaktion.
FAQ
What insider trades did NKTR report on this Form 4?
Were the sales executed under a Rule 10b5-1 plan for NKTR insider Robin Howard?
How many NKTR shares does Robin Howard beneficially own after the reported sales?
What price ranges were disclosed for the NKTR sales?
Who signed the Form 4 for these NKTR transactions?
